MT2024-06: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells(VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic HematopoieticCell Transplantation

Project: Research project

Project Details

Description

MT2024-06: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
StatusActive
Effective start/end date8/12/242/28/34

Funding

  • VOR BIOPHARMA, INC

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.